ROLE OF LOW MOLECULAR WEIGHT HEPARIN IN ADVERSE OBSTETRICAL OUTCOME IN-PATIENTS DUE TO OLIGOHYDROAMNIOS AND SEVERE IUGR

Abstract

Adverse obstetrical outcome means either patients with recurrent abortions or intrauterine death premature delivery due to foetal reasons in which foetus cannot survive in utero because of some hostile conditions like severe intrauterine growth retardation, severe oligohydramnios, or resistant umbilical artery blood flow. Low molecular weight heparin is recommended treatment in anti-phospholipid syndrome which improves perinatal outcome in patients with anti-phospholipid syndrome. Methods: This was an observational, intention-to-treat study conducted at Obs/Gyn Unit, PAF Hospital Lahore from March 2014 to March 2015. Low molecular weight heparin (LMWH) 40 mg subcutaneously daily was used from 16 weeks to 36 weeks of gestation. Hypertension and gestational diabetes was also addressed according to standard operative procedure of the hospital. Results: All 13 patients were delivered at 36 weeks of gestation by lower segment caesarean section. All neonates were delivered with Apgar score of 8/10–10/10. Carry home baby ratio was 100%. Conclusion: Low molecular weight heparin has definitive role in patients with adverse pregnancy outcome due to IUGR and oligohydramnios in the absence of APS and thrombophilias.